These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 35156573)

  • 41. HIV co-receptors as targets for antiviral therapy.
    Schols D
    Curr Top Med Chem; 2004; 4(9):883-93. PubMed ID: 15134547
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of the CXCR4 structure on docking-based virtual screening of HIV entry inhibitors.
    Planesas JM; Pérez-Nueno VI; Borrell JI; Teixidó J
    J Mol Graph Model; 2012 Sep; 38():123-36. PubMed ID: 23079643
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Small molecules anti-HIV therapeutics targeting CXCR4.
    Grande F; Garofalo A; Neamati N
    Curr Pharm Des; 2008; 14(4):385-404. PubMed ID: 18289065
    [TBL] [Abstract][Full Text] [Related]  

  • 44. An expanded model of HIV cell entry phenotype based on multi-parameter single-cell data.
    Bozek K; Eckhardt M; Sierra S; Anders M; Kaiser R; Kräusslich HG; Müller B; Lengauer T
    Retrovirology; 2012 Jul; 9():60. PubMed ID: 22830600
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Non Nucleoside Reverse Transcriptase Inhibitors, Molecular Docking Studies and Antitubercular Activity of Thiazolidin-4-one Derivatives.
    Chitre TS; Patil SM; Sujalegaonkar AG; Asgaonkar KD; Khedkar VM; Garud DR; Jha PC; Gaikwad SY; Kulkarni SS; Choudhari A; Sarkar D
    Curr Comput Aided Drug Des; 2019; 15(5):433-444. PubMed ID: 30574853
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The role of N-glycosylation sites on the CXCR4 receptor for CXCL-12 binding and signaling and X4 HIV-1 viral infectivity.
    Huskens D; Princen K; Schreiber M; Schols D
    Virology; 2007 Jul; 363(2):280-7. PubMed ID: 17331556
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Katy, bar the door! HIV entry inhibitors.
    Martinez LJ
    Res Initiat Treat Action; 2000 Jun; 6(2):6-12. PubMed ID: 11707878
    [No Abstract]   [Full Text] [Related]  

  • 48. Peptide and protein-based inhibitors of HIV-1 co-receptors.
    von Recum HA; Pokorski JK
    Exp Biol Med (Maywood); 2013 May; 238(5):442-9. PubMed ID: 23856897
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inhibition of HIV Fusion by Small Molecule Agonists through Efficacy-Engineering of CXCR4.
    Berg C; Daugvilaite V; Steen A; Jørgensen AS; Våbenø J; Rosenkilde MM
    ACS Chem Biol; 2018 Apr; 13(4):881-886. PubMed ID: 29461034
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Highly specific and sensitive pharmacophore model for identifying CXCR4 antagonists. Comparison with docking and shape-matching virtual screening performance.
    Karaboga AS; Planesas JM; Petronin F; Teixidó J; Souchet M; Pérez-Nueno VI
    J Chem Inf Model; 2013 May; 53(5):1043-56. PubMed ID: 23577723
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Chemokine receptors as new molecular targets for antiviral therapy.
    Santoro F; Vassena L; Lusso P
    New Microbiol; 2004 Apr; 27(2 Suppl 1):17-29. PubMed ID: 15646061
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Structural and Biological Characterizations of Novel High-Affinity Fluorescent Probes with Overlapped and Distinctive Binding Regions on CXCR4.
    Zhu S; Meng Q; Schooley RT; An J; Xu Y; Huang Z
    Molecules; 2019 Aug; 24(16):. PubMed ID: 31412600
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Co-receptor antagonists as HIV-1 entry inhibitors.
    Shaheen F; Collman RG
    Curr Opin Infect Dis; 2004 Feb; 17(1):7-16. PubMed ID: 15090884
    [TBL] [Abstract][Full Text] [Related]  

  • 54. 2-Aminothiazolones as anti-HIV agents that act as gp120-CD4 inhibitors.
    Tiberi M; Tintori C; Ceresola ER; Fazi R; Zamperini C; Calandro P; Franchi L; Selvaraj M; Botta L; Sampaolo M; Saita D; Ferrarese R; Clementi M; Canducci F; Botta M
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3043-52. PubMed ID: 24614386
    [TBL] [Abstract][Full Text] [Related]  

  • 55. HIV-1 Entry and Membrane Fusion Inhibitors.
    Xiao T; Cai Y; Chen B
    Viruses; 2021 Apr; 13(5):. PubMed ID: 33922579
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inhibition of HIV infection by CXCR4 and CCR5 chemokine receptor antagonists.
    De Clercq E; Schols D
    Antivir Chem Chemother; 2001; 12 Suppl 1():19-31. PubMed ID: 11594685
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Upcoming drugs that inhibit viral entry will be a new frontier for antiretroviral therapy.
    Murphy MJ
    HIV Clin; 2002; 14(4):1-3. PubMed ID: 12434756
    [No Abstract]   [Full Text] [Related]  

  • 58. HIV-2 susceptibility to entry inhibitors.
    Borrego P; Taveira N
    AIDS Rev; 2013; 15(1):49-61. PubMed ID: 23449229
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Putative cholesterol-binding sites in human immunodeficiency virus (HIV) coreceptors CXCR4 and CCR5.
    Zhukovsky MA; Lee PH; Ott A; Helms V
    Proteins; 2013 Apr; 81(4):555-67. PubMed ID: 23161741
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The appealing story of HIV entry inhibitors : from discovery of biological mechanisms to drug development.
    Castagna A; Biswas P; Beretta A; Lazzarin A
    Drugs; 2005; 65(7):879-904. PubMed ID: 15892586
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.